Thomas de Vlaam
Co-Founder FL86 @ Flagship Pioneering
Thomas de Vlaam is a seed investor at Flagship Pioneering focused on Health Care and Therapeutics. Thomas de Vlaam is the Co-Founder FL86 at Flagship Pioneering. Thomas de Vlaam attended University of Groningen.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Thomas de Vlaam invests in
Stages Thomas de Vlaam invests in
Countries Thomas de Vlaam invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (33%)
- Therapeutics 1 (33%)
- Biotechnology 1 (33%)
- Pharmaceutical 1 (33%)
Stage
- Seed 2 (67%)
- Pre-Seed 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Metri Bio
|
Metri Bio is a healthcare company that focused on endometrial diseases to improve lives of people. | $5M / Pre-Seed / Dec 02, 2025 | |
Skeletalis
|
Skeletalis is a biotechnology startup focused on developing next-generation precision medicines for musculoskeletal diseases, primarily osteoporosis. | $8M / Seed / Nov 17, 2025 | |
Thymmune Therapeutics
|
Thymmune Therapeutics is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. | $7M / Seed / Mar 01, 2023 |
Co-Investors
About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and grows first-in-category ventures to transform human health and sustainability. The company accelerates Flagship Pioneering’s advances in biology, engineering, medicine, energy, and beyond. The firm harnesses science and entrepreneurialism to envision alternative futures, beginning withseemingly unreasonable propositions and navigating to transformational outcomes through an evolutionary methodology.Flagship Pioneering combines innovative capacity, entrepreneurial leadership, and professional capital management in a single enterprise that systematically produces first-in-category companies.
Flagship Pioneering Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Geoffrey von Maltzahn
General Partner
|
|||
Hari Pujar
Operating Partner
|
|||
Paul Biondi
Executive Partner & President
|
|||
|
Thomas de Vlaam
Co-Founder FL86
|
|||
Avak Kahvejian
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Thomas de Vlaam invest in?
Thomas de Vlaam invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Seed and Pre-Seed stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Thomas de Vlaam?
Public channels for Thomas de Vlaam include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Thomas de Vlaam last invest?
The most recent investment recorded for Thomas de Vlaam closed in Dec 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
